Background
Background Relapse is one of the Relapse is one of the most costly aspects of schizophrenia. most costly aspects of schizophrenia.
Aims Aims To compare costs, clinical
To compare costs, clinical outcomes and quality of life for patients outcomes and quality of life for patients who experienced relapse in schizophrenia who experienced relapse in schizophrenia with a control group who did not relapse. with a control group who did not relapse.
Method Method Patients were randomly
Patients were randomly selected from current psychiatric caseselected from current psychiatric caseloads drawn from urban and suburban loads drawn from urban and suburban areas of Leicester.Differences in costs and areas of Leicester.Differences in costs and outcomes by relapse status in the previous outcomes by relapse status in the previous 6 months were examined using 6 months were examined using parametric and non-parametric tests, and parametric and non-parametric tests, and multivariate analysis was used to examine multivariate analysis was used to examine factors associated with relapse and costs. factors associated with relapse and costs.
Results

Results Costs for the patients who
Costs for the patients who relapsed were over four times higher than relapsed were over four times higher than those for the non-relapse group.There those for the non-relapse group.There were few statistically significantdifferences were few statistically significantdifferences in clinical and quality of life measures by in clinical and quality of life measures by relapse status.Multivariate analyses relapse status.Multivariate analyses suggested some significant correlates of suggested some significant correlates of relapse and costs. relapse and costs.
Conclusions Conclusions The higher costs
The higher costs associated with relapse will be of interest associated with relapse will be of interest to policy-makers who face difficult choices to policy-makers who face difficult choices concerning new but more expensive concerning new but more expensive treatments for patients with treatments for patients with schizophrenia. schizophrenia.
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Symptomatic relapse in schizophrenia is Symptomatic relapse in schizophrenia is both distressing and costly. It can devastate both distressing and costly. It can devastate the lives not only of patients, but also of the lives not only of patients, but also of their families. The debilitating symptoms their families. The debilitating symptoms require specialist health care interventions require specialist health care interventions and targeted treatments, with potentially and targeted treatments, with potentially high costs. It has been estimated, for examhigh costs. It has been estimated, for example, that relapse cost $2 billion just for ple, that relapse cost $2 billion just for readmissions to hospital in the USA, almost readmissions to hospital in the USA, almost a decade ago (Weiden & Olfson, 1995) . a decade ago (Weiden & Olfson, 1995) . There is no equivalent estimate for the There is no equivalent estimate for the UK. This study aimed to compare costs, UK. This study aimed to compare costs, clinical outcomes and quality of life (QoL) clinical outcomes and quality of life (QoL) for patients with schizophrenia in the UK for patients with schizophrenia in the UK according to whether or not they had according to whether or not they had experienced a relapse in the previous 6 experienced a relapse in the previous 6 months. months.
METHOD METHOD
Study sample Study sample
Patients were randomly selected from Patients were randomly selected from current (active) psychiatric case-loads current (active) psychiatric case-loads drawn from urban and suburban areas of drawn from urban and suburban areas of the English city of Leicester. Consultant the English city of Leicester. Consultant psychiatrists or senior responsible medical psychiatrists or senior responsible medical staff were approached by a project research staff were approached by a project research psychiatrist and asked for a list of patients psychiatrist and asked for a list of patients with a possible diagnosis of schizophrenia. with a possible diagnosis of schizophrenia. Full lists were obtained from five consulFull lists were obtained from five consultants covering city and suburban catchment tants covering city and suburban catchment areas of Leicester. An additional five conareas of Leicester. An additional five consultants were also approached to identify sultants were also approached to identify patients with the diagnosis who had experipatients with the diagnosis who had experienced a relapse within the past 6 months. enced a relapse within the past 6 months. Patients were excluded if they were living Patients were excluded if they were living outside this area when the sampling was outside this area when the sampling was undertaken. Patients from rural areas of undertaken. Patients from rural areas of Leicestershire were excluded. The sampling Leicestershire were excluded. The sampling procedure was designed to recruit equal procedure was designed to recruit equal numbers of relapse and non-relapse cases. numbers of relapse and non-relapse cases.
Patients were included as participants if Patients were included as participants if they had received a diagnosis of schizothey had received a diagnosis of schizophrenia according to DSM-IV criteria phrenia according to DSM-IV criteria (American Psychiatric Association, 1994) , (American Psychiatric Association, 1994) , had no other psychosis, were aged 18-64 had no other psychosis, were aged 18-64 years, and gave their informed consent. years, and gave their informed consent.
Patients were excluded from the study if Patients were excluded from the study if they were roofless, continuously hospitalthey were roofless, continuously hospitalised for 12 months or more, about to move ised for 12 months or more, about to move residence, already participating in a clinical residence, already participating in a clinical trial, or unable to participate for language trial, or unable to participate for language reasons. Although such biases were not spereasons. Although such biases were not specifically controlled for, clinicians took every cifically controlled for, clinicians took every step to avoid biases in the socio-economic step to avoid biases in the socio-economic and demographic profiles of patients. and demographic profiles of patients.
Relapse criteria Relapse criteria
Many alternative definitions of relapse in Many alternative definitions of relapse in schizophrenia have been published (see schizophrenia have been published (see Lader, 1995, for review) . These include Lader, 1995, for review) . These include number of admissions to hospital, detennumber of admissions to hospital, detention under a section of the Mental Health tion under a section of the Mental Health Act, attendance at an acute day care cenAct, attendance at an acute day care centre, change of antipsychotic agent, intre, change of antipsychotic agent, increased staff input and/or more intensive creased staff input and/or more intensive case staff management, and a significant case staff management, and a significant change in accommodation. Relapse was change in accommodation. Relapse was identified retrospectively in this study as identified retrospectively in this study as the re-emergence or aggravation of psythe re-emergence or aggravation of psychotic symptoms for at least 7 days during chotic symptoms for at least 7 days during the 6 months prior to the study. In addition the 6 months prior to the study. In addition to instances of relapse pointed out by clinito instances of relapse pointed out by clinical staff, recorded changes in mental state cal staff, recorded changes in mental state were regarded as significant and amounting were regarded as significant and amounting to relapse if there was a clearly documented to relapse if there was a clearly documented assessment of a relapse. A change in manassessment of a relapse. A change in management as appropriate might also have agement as appropriate might also have occurred but not necessarily, and not all reoccurred but not necessarily, and not all relapses led to readmission. Relapse could lapses led to readmission. Relapse could thus be identified in cases of patients who thus be identified in cases of patients who had been admitted to hospital in the past had been admitted to hospital in the past 6 months, who had consulted their psy-6 months, who had consulted their psychiatrist and had had their medication chiatrist and had had their medication changed for deterioration in their condichanged for deterioration in their condition, or who had had an increase in intention, or who had had an increase in intensive support at home from the community sive support at home from the community mental health team. A planned hospital mental health team. A planned hospital admission was not classed as a relapse. A admission was not classed as a relapse. A research team specialist registrar advised research team specialist registrar advised the researcher on any case-note descriptions the researcher on any case-note descriptions or accounts from staff that were unclear. or accounts from staff that were unclear.
Instrumentation Instrumentation
Data were collected especially for this Data were collected especially for this study. Data collection was based on inforstudy. Data collection was based on information obtained directly from case notes mation obtained directly from case notes and from interviews with the patients in and from interviews with the patients in which rating scales were completed which rating scales were completed (patients gave informed written consent). (patients gave informed written consent). (Lehman, 1996) , the visual of Life scale (Lehman, 1996) , the visual analogue scale from the EuroQoL EQ-5D analogue scale from the EuroQoL EQ-5D health-related quality of life measure (Kind, health-related quality of life measure (Kind, 1996) and the Client Service Receipt Inven-1996) and the Client Service Receipt Inventory (CSRI; Beecham & Knapp, 1992, tory (CSRI; Beecham & Knapp, 1992 , 2001 . Unit costs attached to services were 2001). Unit costs attached to services were national average figures for the period over national average figures for the period over which clinical and service use data were which clinical and service use data were collected, at 1998-9 prices (Netten collected, at 1998-9 prices .
Statistical analyses Statistical analyses
Depending on the distribution of key variDepending on the distribution of key variables, parametric (independent ables, parametric (independent t t-test) and -test) and non-parametric (Mann-Whitney, Kruskalnon-parametric (Mann-Whitney, KruskalWallis) tests were carried out to check for Wallis) tests were carried out to check for significant differences in mean costs, clinisignificant differences in mean costs, clinical and QoL outcomes by relapse status. cal and QoL outcomes by relapse status. The Pearson chi-squared statistic was used The Pearson chi-squared statistic was used to test for significant differences between to test for significant differences between categorical measures and relapse status, categorical measures and relapse status, and for other relapse criteria. and for other relapse criteria.
The survey design also permitted multiThe survey design also permitted multivariate analysis to examine simultaneously variate analysis to examine simultaneously some of the potential correlates of relapse some of the potential correlates of relapse status and costs, although it should be status and costs, although it should be noted that the study did not include a full noted that the study did not include a full range of possible associations with relapse range of possible associations with relapse (see for example, Robinson (see for example, Robinson et al et al, 1999) . , 1999). First, a generalised linear model (GLM) First, a generalised linear model (GLM) with a logit link function was used to with a logit link function was used to predict whether a patient had experienced predict whether a patient had experienced a relapse or not. The logit GLM is similar a relapse or not. The logit GLM is similar to the standard logistic model but also proto the standard logistic model but also produces a measure of dispersion (the variance duces a measure of dispersion (the variance of the unexplained part of the model). Odds of the unexplained part of the model). Odds ratios are presented which show the likeliratios are presented which show the likelihood of relapse given particular patient hood of relapse given particular patient characteristics. Second, because costs were characteristics. Second, because costs were skewed to the right (although only 5% skewed to the right (although only 5% were zero values), standard ordinary least were zero values), standard ordinary least squares estimates were inappropriate (cf. squares estimates were inappropriate (cf. Dunn Dunn et al et al, 2003) . The results presented , 2003) . The results presented are based on a reduced-form GLM model, are based on a reduced-form GLM model, with a log link function and a Gaussian varwith a log link function and a Gaussian variance function. Compared with other standiance function. Compared with other standard GLM specifications, this produced the ard GLM specifications, this produced the best-fitting model in terms of mean best-fitting model in terms of mean predicted cost levels. It also produced the predicted cost levels. It also produced the most efficient estimates in terms of lower most efficient estimates in terms of lower standard errors and smaller confidence standard errors and smaller confidence intervals. The statistical analyses were carintervals. The statistical analyses were carried out using the Statistical Package for ried out using the Statistical Package for the Social Sciences version 9 for descriptive the Social Sciences version 9 for descriptive comparisons and STATA version 6 for the comparisons and STATA version 6 for the multivariate analyses. multivariate analyses.
RESULTS RESULTS
Sample Sample
We identified 257 patients potentially eligiWe identified 257 patients potentially eligible to participate in the study. Of these, 12 ble to participate in the study. Of these, 12 refused to take part, 67 were not interrefused to take part, 67 were not interviewed because of staff concerns, 12 could viewed because of staff concerns, 12 could not be contacted, and 9 were judged by not be contacted, and 9 were judged by the interviewer to be too ill; in three cases the interviewer to be too ill; in three cases it was felt to be unsafe to see the patient it was felt to be unsafe to see the patient at home. at home.
A total of 145 patients completed inter-A total of 145 patients completed interviews in the study: 77 relapse cases and 68 views in the study: 77 relapse cases and 68 non-relapse cases. Another 9 patients who non-relapse cases. Another 9 patients who were also interviewed were excluded were also interviewed were excluded because of incomplete records or inconsisbecause of incomplete records or inconsistent data. The limited information available tent data. The limited information available on them suggests that most would have on them suggests that most would have been assigned to the non-relapse group been assigned to the non-relapse group and, if included, their cases would have and, if included, their cases would have had little impact on average costs. had little impact on average costs.
Relapse and patient characteristics Relapse and patient characteristics
Relapse status was defined on the basis of Relapse status was defined on the basis of re-emergence or aggravation of psychotic re-emergence or aggravation of psychotic symptoms. Table 1 lists other patient charsymptoms. Table 1 lists other patient characteristics previously employed to define acteristics previously employed to define relapse . Not surprisingly, relapse . Not surprisingly, relapse cases were characterised by higher relapse cases were characterised by higher rates of hospitalisation (63%), rerates of hospitalisation (63%), reemergence of psychotic symptoms (60%) emergence of psychotic symptoms (60%) and aggravation of positive or negative and aggravation of positive or negative symptoms (43%), and an increased level symptoms (43%), and an increased level of staff input or more intensive case staff of staff input or more intensive case staff management (33%) (all management (33%) (all P P5 50.05). 0.05). Compared with the non-relapse group, Compared with the non-relapse group, patients who had recently experienced a patients who had recently experienced a relapse had been more recently admitted relapse had been more recently admitted to a psychiatric ward (using actual years: to a psychiatric ward (using actual years: 1997 and 1992, 1997 and 1992, P P5 50.05) , and experienced 0.05), and experienced a higher number of admissions (5.6 and a higher number of admissions (5.6 and 3.3, 3.3, P P5 50.05) . Although patients in the 0.05). Although patients in the non-relapse group appeared to have spent non-relapse group appeared to have spent longer in hospital, the difference was not longer in hospital, the difference was not significant (Table 2 ). There was no differsignificant (Table 2 ). There was no difference between the relapse and non-relapse ence between the relapse and non-relapse groups with respect to gender, ethnic groups with respect to gender, ethnic group, marital status, employment status group, marital status, employment status or highest level of education (Table 3) . or highest level of education (Table 3) Clinical health and quality of life Clinical health and quality of life Although higher scores on the PANSS and Although higher scores on the PANSS and the CGI suggested worse symptoms for the CGI suggested worse symptoms for relapse compared with non-relapse cases, relapse compared with non-relapse cases, the differences were not statistically signifithe differences were not statistically significant. However, GAF scores indicated worse cant. However, GAF scores indicated worse symptoms for relapse patients ( symptoms for relapse patients (P P5 50.05; 0.05; Table 4 ). Table 4) .
Using the Lehman 'delighted-terrible' Using the Lehman 'delighted-terrible' (D-T) scale and scores, relapse patients (D-T) scale and scores, relapse patients appeared to experience lower QoL than appeared to experience lower QoL than non-relapse patients on most dimensions, non-relapse patients on most dimensions, but the differences were small and not but the differences were small and not statistically significant, except for the items statistically significant, except for the items 'living arrangements' and 'feelings about 'living arrangements' and 'feelings about current health' ( current health' (P P5 50.05). There was per-0.05). There was perhaps some inconsistency in the QoL findings haps some inconsistency in the QoL findings since relapse patients scored slightly better since relapse patients scored slightly better 3 4 7 3 4 7 on the EQ-5D visual analogue scale on the EQ-5D visual analogue scale compared with non-relapse patients compared with non-relapse patients ( (P P5 50.05). 0.05). However, the EQ-5D measures However, the EQ-5D measures own health state today, whereas the own health state today, whereas the Lehman score covers broader dimensions Lehman score covers broader dimensions of quality of life. of quality of life.
Resources and costs Resources and costs
Six-month service use rates and costs per Six-month service use rates and costs per patient are summarised in Table 5 . Costs patient are summarised in Table 5 . Costs for relapse cases were four times higher for relapse cases were four times higher than those for non-relapse cases -£8212 than those for non-relapse cases -£8212 compared with £1899 ( compared with £1899 (P P5 50.05) -with 0.05) -with much of the cost difference accounted for much of the cost difference accounted for by in-patient days. During the 6 months by in-patient days. During the 6 months prior to the study, patients in the relapse prior to the study, patients in the relapse group spent a mean of 58 days in hospigroup spent a mean of 58 days in hospital -although this figure was inflated by tal -although this figure was inflated by six patients who were continuously in hossix patients who were continuously in hospital for the entire period. By design and pital for the entire period. By design and selection, nobody in the non-relapse group selection, nobody in the non-relapse group experienced any hospitalisation in this experienced any hospitalisation in this period. period.
Psychiatric out-patient visits were also Psychiatric out-patient visits were also significantly more common in relapse than significantly more common in relapse than in non-relapse cases (mean cost £209 in non-relapse cases (mean cost £209 v v. . £135, £135, P P5 50.05). On the other hand, there 0.05). On the other hand, there was slightly higher use by patients in the was slightly higher use by patients in the non-relapse group of day care centres, non-relapse group of day care centres, group therapy, sheltered workshops, spegroup therapy, sheltered workshops, specialist education, general practitioners and cialist education, general practitioners and community psychiatric nurse (CPN) visits, community psychiatric nurse (CPN) visits, but apart from day care centres none of but apart from day care centres none of the differences was statistically significant the differences was statistically significant at the 5% level. Services are complements, at the 5% level. Services are complements, in the sense that patients with greater morin the sense that patients with greater morbidity are likely to use more of a number of bidity are likely to use more of a number of 3 4 8 3 4 8 services, but are also substitutes, in that services, but are also substitutes, in that (for example) hospital in-patients will have (for example) hospital in-patients will have less need and less opportunity to use day less need and less opportunity to use day care, primary care and CPN support. These care, primary care and CPN support. These two tendencies may have cancelled out for two tendencies may have cancelled out for this sample. this sample.
Relapse correlates Relapse correlates
Given the (expected) high costs associated Given the (expected) high costs associated with illness relapse, correlates of relapse with illness relapse, correlates of relapse and non-relapse status were examined. and non-relapse status were examined. The odds ratios in Table 6 indicate that, The odds ratios in Table 6 
Cost correlates Cost correlates
The log link method of GLM estimation The log link method of GLM estimation was used to examine the factors associated was used to examine the factors associated with cost differences (Table 7) . Coefficient with cost differences (Table 7) . Coefficient values represent the percentage change in values represent the percentage change in total costs (from the average) following a total costs (from the average) following a one-unit change in the explanatory varione-unit change in the explanatory variable (compared with a reference category able (compared with a reference category if the variable is categorical). Holding conif the variable is categorical). Holding constant all other explanatory factors in the stant all other explanatory factors in the model, average costs were increased by model, average costs were increased by patients who relapsed (147%), and were patients who relapsed (147%), and were reduced by patients who were older reduced by patients who were older (3.6% per year of age), and living with (3.6% per year of age), and living with family/others compared with those in family/others compared with those in collective accommodation (58%). collective accommodation (58%).
DISCUSSION DISCUSSION
Costs of relapse of schizophrenia Costs of relapse of schizophrenia
Studies of the overall costs of schizophrenia Studies of the overall costs of schizophrenia in the UK (Davies & Drummond, 1993) in the UK (Davies & Drummond, 1993) and in other countries (Knapp and in other countries , 2004) confirm the high proportion of the total confirm the high proportion of the total that is attributable to in-patient care. This that is attributable to in-patient care. This study shows that illness relapse is a major study shows that illness relapse is a major factor in generating these high hospitalisafactor in generating these high hospitalisation rates and costs. We have gone further, tion rates and costs. We have gone further, however, in providing an estimate of the however, in providing an estimate of the full service costs of schizophrenia relapse full service costs of schizophrenia relapse in the UK. Patients who experienced a rein the UK. Patients who experienced a relapse during the 6 months prior to data collapse during the 6 months prior to data collection had mean service costs of £8212 lection had mean service costs of £8212 compared with £1899 for those who had compared with £1899 for those who had no relapse during this period. The only preno relapse during this period. The only previous UK estimate of the costs of relapse of vious UK estimate of the costs of relapse of which we are aware was based on expert which we are aware was based on expert opinion and assumed (rather than obopinion and assumed (rather than observed) service utilisation in a simulation served) service utilisation in a simulation model that compared three antipsychotic model that compared three antipsychotic drugs (Almond & O'Donnell, 2000) . Averdrugs (Almond & O'Donnell, 2000) . Average relapse costs at 1997 prices were estiage relapse costs at 1997 prices were estimated to be just over £10 000 per patient mated to be just over £10 000 per patient during three monthly cycles and included during three monthly cycles and included both service use costs and accommodation both service use costs and accommodation costs (the latter not included here). costs (the latter not included here).
Clinical and QoL correlates Clinical and QoL correlates
Surprisingly, perhaps, there were few differSurprisingly, perhaps, there were few differences in clinical and QoL outcomes beences in clinical and QoL outcomes between patients who had relapsed and tween patients who had relapsed and those who had not. However, some of the those who had not. However, some of the patients in the former group would have repatients in the former group would have recovered well from their relapse by the time covered well from their relapse by the time these clinical and QoL instruments were these clinical and QoL instruments were 3 4 9 3 4 9 Table 5  Table 5 Mean 6-month service use and costs (», 1998) administered. This time lapse is probably administered. This time lapse is probably the reason for the lack of difference. the reason for the lack of difference.
Associations Associations
Multivariate analyses confirmed some Multivariate analyses confirmed some significant correlates of relapse, and a significant correlates of relapse, and a reduced-form reduced-form cost equation found, as cost equation found, as expected, that relapse status significantly expected, that relapse status significantly increased total costs. The cost equation increased total costs. The cost equation was estimated in reduced form for two was estimated in reduced form for two main reasons. First, relapse status as a main reasons. First, relapse status as a regressor captured some of the important regressor captured some of the important partial effects already identified in the partial effects already identified in the relapse function -for example, suicide relapse function -for example, suicide attempts, previous hospital admissions attempts, previous hospital admissions and social functioning -and reduced the and social functioning -and reduced the need to include these variables further as need to include these variables further as independent effects in the cost analyses. independent effects in the cost analyses. Second, clinical and QoL variables were Second, clinical and QoL variables were excluded from the cost equation because it excluded from the cost equation because it was difficult to relate current measures was difficult to relate current measures with costs in the previous 6 months. This with costs in the previous 6 months. This is a problem of endogeneity: it is difficult is a problem of endogeneity: it is difficult to ascertain the direction of causation to ascertain the direction of causation between variables. Although higher levels between variables. Although higher levels of service use (and costs) might have of service use (and costs) might have improved health and reduced the likelihood improved health and reduced the likelihood of relapse, relapse status might have of relapse, relapse status might have increased service use and costs. However, increased service use and costs. However, given that relapse often resulted in hospitagiven that relapse often resulted in hospitalisation (for about two-thirds of the people lisation (for about two-thirds of the people in the relapse group) and in-patient costs in the relapse group) and in-patient costs accounted for around three-quarters of accounted for around three-quarters of total costs, the problem of endogeneity total costs, the problem of endogeneity with relapse status was less of an issue. with relapse status was less of an issue.
Finally, a cautionary note is required Finally, a cautionary note is required on measuring differences in costs and on measuring differences in costs and health outcomes between the relapse and health outcomes between the relapse and non-relapse groups. Although this method non-relapse groups. Although this method is valid, a superior comparison would come is valid, a superior comparison would come from panel or longitudinal data that meafrom panel or longitudinal data that measure changes in outcomes prospectively sure changes in outcomes prospectively for a given population (cf. Robinson for a given population (cf. Robinson et al et al, , 1999) . The costs of relapse would then be 1999). The costs of relapse would then be estimated by examining the differences in estimated by examining the differences in costs, before, during and after relapse. costs, before, during and after relapse. Cost-effectiveness comparisons are also Cost-effectiveness comparisons are also required based on experimental evaluations required based on experimental evaluations of relapse minimisation strategies. of relapse minimisation strategies.
Policy implications Policy implications
The significant costs found to be associated The significant costs found to be associated with relapse confirm the scale of the with relapse confirm the scale of the impact -in this case measured by service impact -in this case measured by service uptake -of a worsening of symptoms for uptake -of a worsening of symptoms for people with schizophrenia. These costs will people with schizophrenia. These costs will be of interest to clinicians and other decibe of interest to clinicians and other decision-makers who face difficult choices sion-makers who face difficult choices about new but more expensive treatments about new but more expensive treatments for patients with schizophrenia. Subject to for patients with schizophrenia. Subject to the above cautionary comment, delaying the above cautionary comment, delaying the time to relapse should mean delaying the time to relapse should mean delaying the escalation of costs. More importantly, the escalation of costs. More importantly, a slower or reduced rate of relapse means a slower or reduced rate of relapse means slower or reduced damage to the health slower or reduced damage to the health and quality of life of patients, and in some and quality of life of patients, and in some cases also less adverse impact on their cases also less adverse impact on their families. families.
Psychoeducation and related proPsychoeducation and related programmes have been shown to reduce medigrammes have been shown to reduce medication non-adherence, detect prodromal cation non-adherence, detect prodromal symptoms of relapse and reduce the rate symptoms of relapse and reduce the rate of hospitalisation (e.g. Birchwood of hospitalisation (e.g. Birchwood et al et al, , 1989; Kemp 1989; Kemp et al et al, 1996; Herz , 1996; Herz et al et al, , 2000) . A relatively inexpensive evidence-2000). A relatively inexpensive evidencebased intervention for reducing relapse is based intervention for reducing relapse is family work for patients with schizofamily work for patients with schizophrenia living with a relative with high phrenia living with a relative with high levels of expressed emotion (e.g. Xiong levels of expressed emotion (e.g. Xiong et et al al, 1994) . There is no evidence that these , 1994). There is no evidence that these effective interventions have yet come into effective interventions have yet come into widespread use. widespread use.
If new antipsychotic treatments in If new antipsychotic treatments in schizophrenia can improve efficacy and schizophrenia can improve efficacy and compliance rates compared with convencompliance rates compared with conventional neuroleptic therapy, and thereby tional neuroleptic therapy, and thereby reduce relapse rates, this might bring about reduce relapse rates, this might bring about reductions in the service costs of schizoreductions in the service costs of schizophrenia. In turn, as demonstrated in some phrenia. In turn, as demonstrated in some international studies (Hamilton international studies (Hamilton et al et al, , 1999) , and as concluded by the National 1999), and as concluded by the National Institute for Clinical Excellence (2002), Institute for Clinical Excellence (2002) , the overall costs of the treatment could be the overall costs of the treatment could be reduced. reduced. The strongest predictor of illness relapse was associated with patients who had made previous suicide or self-harm attempts. made previous suicide or self-harm attempts.
& & Differences in the quality of life between relapse and non-relapse cases, as
Differences in the quality of life between relapse and non-relapse cases, as measured by the Lehman scale, were generally not significant. measured by the Lehman scale, were generally not significant.
LIMITATIONS LIMITATIONS
& & The study was cross-sectional, and limited to one geographical area of the UK.
The study was cross-sectional, and limited to one geographical area of the UK.
& & Relapse was not studied as it occurred, but in a retrospective design. Relapse was not studied as it occurred, but in a retrospective design.
& & Multivariate analysis was applied to a small sample of patients and with only a few Multivariate analysis was applied to a small sample of patients and with only a few explanatory variables. explanatory variables.
